Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-22-047649

Options or other derivatives

  • Chief Business Officer acquired 130,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Hanley Jr. Michael Conick Chief Business Officer 2022-08-23 Grant or award · Employee Stock Option (right to buy) +130,000 130,000 D
Loading xslF345X03/doc4.xml…